Advertisement
Human Albumin 12.5g/vial (25%, 50 ml), contains the highest concentrationand delivers the highest dosage of the Human Albumin family products inMainland China, and has a better effect on the clinical application forascites due to liver cirrhosis, external injuries, hydrocephalus due tocerebral hemorrhage, serious hypoproteinemia, and other major diseases. Withthis approval, CBP is now one of the few producers offering the widest rangeof Human Albumin products available in China.
Advertisement
"We are pleased to receive approval from the SFDA to produce thisconcentration and dosage of Human Albumin," said Mr. Chaoming Zhao, CFO ofChina Biologic. "The approval represents a significant milestone for ourCompany."
The Company has already commenced the production and marketing of this newproduct.
About China Biologic Products, Inc.
Through its indirect majority-owned subsidiary Shandong Taibang BiologicalProducts Co. Ltd., China Biologic Products, Inc. (the "Company"), isprincipally engaged in the research, development, production and manufacturingand sale of plasma-based biopharmaceutical products to hospitals and otherhealth care facilities in China. The Company's human albumin products aremainly used to increase blood volume and its immunoglobulin products are usedfor the treatment and prevention diseases.
Safe Harbor Statement
This release may contain certain "forward-looking statements" relating tothe business of China Biologic Products, Inc. and its subsidiary companies.All statements, other than statements of historical fact included herein are"forward-looking statements," including statements regarding: the significanceof the new Human Albumin product to the Company, the ability of the Company toachieve its commercial objectives; the business strategy, plans and objectivesof the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identifiedby the use of forward-looking terminology such as "believes," "expects" orsimilar expressions, involve known and unknown risks and uncertainties.Although the Company believes that the expectations reflected in theseforward-looking statements are reasonable, they do involve assumptions, risksand uncertainties, and these expectations may prove to be incorrect. Investorsshould not place undue reliance on these forward-looking statements, whichspeak only as of the date of this press release. The Company's actual resultscould differ materially from those anticipated in these forward-lookingstatements as a result of a variety of factors, including those discussed inthe Company's periodic reports that are filed with the Securities and ExchangeCommission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalfare expressly qualified in their entirety by these factors. Other than asrequired under the securities laws, the Company does not assume a duty toupdate these forward-looking statements.For more information, please contact: Company Contact: Mr. Y. Tristan Kuo Vice President, Finance China Biologic Products, Inc. Tel: +86-538-6202206 Email: [email protected] Web: http://www.chinabiologic.com Investor Relations Contact: Mr. Crocker Coulson President CCG Elite Investor Relations Tel: +1-646-213-1915 (NY office) Email: [email protected] Web: http://www.ccg
